Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Niagen Bioscience (NAGE) over the last 16 years, with Q3 2025 value amounting to $1.8 million.

  • Niagen Bioscience's Share-based Compensation rose 13891.16% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year increase of 2867.29%. This contributed to the annual value of $3.7 million for FY2024, which is 2304.78% down from last year.
  • Latest data reveals that Niagen Bioscience reported Share-based Compensation of $1.8 million as of Q3 2025, which was up 13891.16% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Share-based Compensation registered a high of $1.9 million during Q1 2022, and its lowest value of $735000.0 during Q3 2024.
  • In the last 5 years, Niagen Bioscience's Share-based Compensation had a median value of $1.3 million in 2021 and averaged $1.3 million.
  • In the last 5 years, Niagen Bioscience's Share-based Compensation crashed by 3419.87% in 2024 and then skyrocketed by 13891.16% in 2025.
  • Over the past 5 years, Niagen Bioscience's Share-based Compensation (Quarter) stood at $1.5 million in 2021, then dropped by 9.98% to $1.3 million in 2022, then fell by 21.79% to $1.0 million in 2023, then decreased by 27.48% to $752000.0 in 2024, then soared by 133.51% to $1.8 million in 2025.
  • Its Share-based Compensation was $1.8 million in Q3 2025, compared to $1.5 million in Q2 2025 and $1.1 million in Q1 2025.